Exact Mass: 275.2029

Exact Mass Matches: 275.2029

Found 202 metabolites which its exact mass value is equals to given mass value 275.2029, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Physostigmine

(3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-methylcarbamate; 2-hydroxybenzoic acid

C15H21N3O2 (275.1634)


Physostigmine is a white, odorless, microcrystalline powder. Used as a cholinergic (anticholinesterase) agent and as a veterinary medication. (EPA, 1998) Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning. A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. Physostigmine is a natural product found in Streptomyces griseofuscus, Streptomyces, and other organisms with data available. A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. See also: Physostigmine Salicylate (active moiety of). A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. [PubChem] S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EB - Parasympathomimetics V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AB - Antidotes D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D008916 - Miotics C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D004791 - Enzyme Inhibitors KEIO_ID E007; [MS2] KO008958 KEIO_ID E007

   

Cyclobenzaprine

dimethyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ylidene}propyl)amine

C20H21N (275.1674)


Cyclobenzaprine is a skeletal muscle relaxant and a central nervous system (CNS) depressant. Cyclobenzaprine acts on the locus coeruleus where it results in increased norepinephrine release, potentially through the gamma fibers which innervate and inhibit the alpha motor neurons in the ventral horn of the spinal cord. It is structurally similar to Amitriptyline, differing by only one double bond. D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents M - Musculo-skeletal system > M03 - Muscle relaxants > M03B - Muscle relaxants, centrally acting agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant

   

Pyrodone

4-(2-ethylhexyl)-4-azatricyclo[5.2.1.0²,⁶]dec-8-ene-3,5-dione

C17H25NO2 (275.1885)


   
   
   

Arginylthreonine

(2S,3R)-2-{[(2S)-2-amino-5-carbamimidamido-1-hydroxypentylidene]amino}-3-hydroxybutanoate

C10H21N5O4 (275.1593)


Arginylthreonine is a dipeptide composed of arginine and threonine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

Threonylarginine

(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-5-carbamimidamidopentanoic acid

C10H21N5O4 (275.1593)


Threonylarginine is a dipeptide composed of threonine and arginine. It is an incomplete breakdown product of protein digestion or protein catabolism. Dipeptides are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Some dipeptides are known to have physiological or cell-signalling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

3-Hydroxyhexanoylcarnitine

3-Hydroxyhexanoylcarnitine

C13H25NO5 (275.1733)


Hydroxyhexanoycarnitine is an acylcarnitine. More specifically, it is an hydroxyhexanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Hydroxyhexanoycarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine hydroxyhexanoycarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Citronellyl anthranilate

6-Octen-1-ol, 3,7-dimethyl-, 1-(2-aminobenzoate)

C17H25NO2 (275.1885)


Citronellyl anthranilate is used as a food additive [EAFUS] ("EAFUS: Everything Added to Food in the United States. [http://www.eafus.com/]") It is used as a food additive .

   

4-Hydroxyhexanoycarnitine

3-[(4-hydroxyhexanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C13H25NO5 (275.1733)


4-Hydroxyhexanoycarnitine is an acylcarnitine. More specifically, it is an 4-hydroxyhexanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Hydroxyhexanoycarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Hydroxyhexanoycarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. 4-Hydroxyhexanoycarnitine is elevated in the urine of individuals with metabolic syndrome (PMID: 33295818). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5R)-5-Hydroxyhexanoylcarnitine

3-[(5-hydroxyhexanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C13H25NO5 (275.1733)


(5R)-5-hydroxyhexanoylcarnitine is an acylcarnitine. More specifically, it is an (5R)-5-hydroxyhexanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5R)-5-hydroxyhexanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (5R)-5-hydroxyhexanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. (5R)-5-hydroxyhexanoylcarnitine is elevated in the urine of individuals with metabolic syndrome (PMID: 33295818). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxyprimaquine

8-[(5-aminopentan-2-yl)amino]-6-methoxyquinolin-5-ol

C15H21N3O2 (275.1634)


   

Corydendramine B

Corydendramine B

C18H29NO (275.2249)


   
   

Corydendramine A

Corydendramine A

C18H29NO (275.2249)


   
   

Hazaleamide

Hazaleamide

C18H29NO (275.2249)


   

Oprea1_467403

Oprea1_467403

C20H21N (275.1674)


   

2,3-Dihydro-Mantella Alkalod 241F

2,3-Dihydro-Mantella Alkalod 241F

C17H25NO2 (275.1885)


   

Siphonodictidine

Siphonodictidine

C16H25N3O (275.1998)


   
   

3,4-Dihydro-Mantella Alkalod 241F

3,4-Dihydro-Mantella Alkalod 241F

C17H25NO2 (275.1885)


   
   

2,4,8,11-Tetradecatetraenoic aicd isobutylamide|hazaleamide|N-isobutyl-(2E,4E,8Z,11Z)-tetradecatetraenamide

2,4,8,11-Tetradecatetraenoic aicd isobutylamide|hazaleamide|N-isobutyl-(2E,4E,8Z,11Z)-tetradecatetraenamide

C18H29NO (275.2249)


   
   
   

1-[6-(2-hydroxy-2-phenyl-ethyl)-1-methyl-1,2,3,6-tetrahydro-pyridin-2-yl]-propan-2-ol|Sedacrin|Sedinin

1-[6-(2-hydroxy-2-phenyl-ethyl)-1-methyl-1,2,3,6-tetrahydro-pyridin-2-yl]-propan-2-ol|Sedacrin|Sedinin

C17H25NO2 (275.1885)


   

Crucigasterin 275

Crucigasterin 275

C18H29NO (275.2249)


   

2-Methyl-12-(3-pyridyl)dodecanal

2-Methyl-12-(3-pyridyl)dodecanal

C18H29NO (275.2249)


   

1,3-dideoxy-alpha-1-C-(8-hydroxyoctyl)mannojirimycin

1,3-dideoxy-alpha-1-C-(8-hydroxyoctyl)mannojirimycin

C14H29NO4 (275.2096)


   

lycobscurine A

lycobscurine A

C17H25NO2 (275.1885)


   

2-phenyl-1,5,9-triazacyclotridecan-4-one

2-phenyl-1,5,9-triazacyclotridecan-4-one

C16H25N3O (275.1998)


   

O-methyldihydrojoubertiamine|O-methyldihydrojourbetiamine

O-methyldihydrojoubertiamine|O-methyldihydrojourbetiamine

C17H25NO2 (275.1885)


   

ACMC-20mkiq

ACMC-20mkiq

C18H29NO (275.2249)


   

6-[2-(1-hydroxybutyl)-4-methylphenyl]hex-5-enamide

6-[2-(1-hydroxybutyl)-4-methylphenyl]hex-5-enamide

C17H25NO2 (275.1885)


   

N-((R)-3-Hydroxy-decanoyl)-L-serin|N-((R)-3-hydroxy-decanoyl)-L-serine|Serratamic acid|Serrataminsaeure

N-((R)-3-Hydroxy-decanoyl)-L-serin|N-((R)-3-hydroxy-decanoyl)-L-serine|Serratamic acid|Serrataminsaeure

C13H25NO5 (275.1733)


   

2-[6-(2-Hydroxy-propyl)-1-methyl-[2]piperidyl]-1-phenyl-aethanon|2-[6-(2-hydroxy-propyl)-1-methyl-[2]piperidyl]-1-phenyl-ethanone

2-[6-(2-Hydroxy-propyl)-1-methyl-[2]piperidyl]-1-phenyl-aethanon|2-[6-(2-hydroxy-propyl)-1-methyl-[2]piperidyl]-1-phenyl-ethanone

C17H25NO2 (275.1885)


   
   

Hydroxy-??-Sanshool

Hydroxy-??-Sanshool

C17H25NO2 (275.1885)


   

Eserine

Physostigmine

C15H21N3O2 (275.1634)


relative retention time with respect to 9-anthracene Carboxylic Acid is 0.444 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.438

   

Physostigmine

NCGC00093889-13_C15H21N3O2_Antilirium

C15H21N3O2 (275.1634)


CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5547; ORIGINAL_PRECURSOR_SCAN_NO 5545 S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EB - Parasympathomimetics V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AB - Antidotes D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D008916 - Miotics C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D004791 - Enzyme Inhibitors CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5557; ORIGINAL_PRECURSOR_SCAN_NO 5556 CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5565; ORIGINAL_PRECURSOR_SCAN_NO 5563 CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5582; ORIGINAL_PRECURSOR_SCAN_NO 5581 CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5563; ORIGINAL_PRECURSOR_SCAN_NO 5562 CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5574; ORIGINAL_PRECURSOR_SCAN_NO 5571 Formula(Parent): C15H21N3O2; Bottle Name:Eserine; PRIME Parent Name:Eserine / Physostigmine; PRIME in-house No.:V0352 0226; SubCategory_DNP: Alkaloids derived from tryptophan, Simple tryptamine alkaloids, Indole alkaloids Annotation level-1

   

phenylethylamide 275

phenylethylamide 275

C18H29NO (275.2249)


   

N-Acetyl-5-hydroxytryptamine

N-Acetyl-5-hydroxytryptamine

C15H21N3O2 (275.1634)


   

4-(5H-Dibenzo[a.d]cycloheptan-5-ylidene)piperidin

4-(5H-Dibenzo[a.d]cycloheptan-5-ylidene)piperidin

C20H21N (275.1674)


   

5-Hydroxyprimaquine

5-Hydroxyprimaquine

C15H21N3O2 (275.1634)


   
   
   

(8S,Z)-6-((R,E)-2,5-dimethylhepta-4,6-dien-1-ylidene)-8-methyloctahydroindolizin-8-ol

(8S,Z)-6-((R,E)-2,5-dimethylhepta-4,6-dien-1-ylidene)-8-methyloctahydroindolizin-8-ol

C18H29NO (275.2249)


   
   

N-(3S-hydroxydecanoyl)-L-serine

N-(3S-hydroxydecanoyl)-L-serine

C13H25NO5 (275.1733)


   

Arg-THR

2-(2-amino-3-hydroxybutanamido)-5-carbamimidamidopentanoic acid

C10H21N5O4 (275.1593)


   

THR-Arg

2-(2-amino-5-carbamimidamidopentanamido)-3-hydroxybutanoic acid

C10H21N5O4 (275.1593)


A dipeptide formed from L-threonine and L-arginine residues.

   

Serratamic acid

N-(3S-hydroxydecanoyl)-L-serine

C13H25NO5 (275.1733)


   

CAR 6:0;O

(3S)-3-[(3-hydroxyhexanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C13H25NO5 (275.1733)


   

4-Piperidinecarboxamide,4-[(1-methylethyl)amino]-1-(phenylmethyl)-

4-Piperidinecarboxamide,4-[(1-methylethyl)amino]-1-(phenylmethyl)-

C16H25N3O (275.1998)


   

4-Decylphenyl isothiocyanate

4-Decylphenyl isothiocyanate

C17H25NS (275.1708)


   

1,2,5-Trimethyl-4-phenyl-4-propionoxypiperidine

[(2S,5R)-1,2,5-trimethyl-4-phenylpiperidin-4-yl] propanoate

C17H25NO2 (275.1885)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics

   

tert-butyl 3-[(dimethylamino)methyl]pyrrolo[2,3-b]pyridine-1-carboxylate

tert-butyl 3-[(dimethylamino)methyl]pyrrolo[2,3-b]pyridine-1-carboxylate

C15H21N3O2 (275.1634)


   

propiram

propiram

C16H25N3O (275.1998)


C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist

   

Betameprodina

(3-ethyl-1-methyl-4-phenylpiperidin-4-yl) propanoate

C17H25NO2 (275.1885)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent

   

Ametoctradin

5-ethyl-6-octyl-[1,2,3]triazolo[1,5-a]pyrimidin-7-amine

C15H25N5 (275.211)


   
   

octriptyline

octriptyline

C20H21N (275.1674)


   

ethyl 4-[(benzylamino)methyl]cyclohexanecarboxylate

ethyl 4-[(benzylamino)methyl]cyclohexanecarboxylate

C17H25NO2 (275.1885)


   

Tributylmethylammonium methyl carbonate

Tributylmethylammonium methyl carbonate

C15H33NO3 (275.246)


   

5-(dibutylamino)-2-nitrobenzonitrile

5-(dibutylamino)-2-nitrobenzonitrile

C15H21N3O2 (275.1634)


   

Ethyl N-Boc-4-fluoropiperidine-4-carboxylate

Ethyl N-Boc-4-fluoropiperidine-4-carboxylate

C13H22FNO4 (275.1533)


   

5,6-Dimethoxy-2-[(4-piperidyl)methyl]indane

5,6-Dimethoxy-2-[(4-piperidyl)methyl]indane

C17H25NO2 (275.1885)


   
   

N-(4-TERT-BUTYLBENZYL)PIPERIDINE-4-CARBOXYLIC ACID

N-(4-TERT-BUTYLBENZYL)PIPERIDINE-4-CARBOXYLIC ACID

C17H25NO2 (275.1885)


   

TERT-BUTYL 2-(TERT-BUTYLDIMETHYLSILYLOXY)ETHYLCARBAMATE

TERT-BUTYL 2-(TERT-BUTYLDIMETHYLSILYLOXY)ETHYLCARBAMATE

C13H29NO3Si (275.1917)


   

Ethyl 1-Boc-3-fluoropiperidine-3-carboxylate

Ethyl 1-Boc-3-fluoropiperidine-3-carboxylate

C13H22FNO4 (275.1533)


   

(CYCLOHEXYLAMINOMETHYL)TRIETHOXYSILANE

(CYCLOHEXYLAMINOMETHYL)TRIETHOXYSILANE

C13H29NO3Si (275.1917)


   

tri-n-butyl-d27 phosphate

tri-n-butyl-d27 phosphate

C12H18D9O4P (275.2212)


   

2-NITRO-2-UNDECYL-1,3-PROPANEDIOL

2-NITRO-2-UNDECYL-1,3-PROPANEDIOL

C14H29NO4 (275.2096)


   

4-METHYL-7-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3,4-DIHYDRO-2H-1,4-BENZOXAZINE

4-METHYL-7-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3,4-DIHYDRO-2H-1,4-BENZOXAZINE

C15H22BNO3 (275.1693)


   

2-(cyclopropylmethoxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

2-(cyclopropylmethoxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

C15H22BNO3 (275.1693)


   

Propipocaine

Propipocaine

C17H25NO2 (275.1885)


C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent

   

tert-butyl 2-benzylpiperidine-1-carboxylate

tert-butyl 2-benzylpiperidine-1-carboxylate

C17H25NO2 (275.1885)


   

3-(N,N-Dimethylaminocarbonyl)phenylboronic acid pinacol ester

3-(N,N-Dimethylaminocarbonyl)phenylboronic acid pinacol ester

C15H22BNO3 (275.1693)


   

N-(4-tert-Butylphenyl)-2-naphthylamine

N-(4-tert-Butylphenyl)-2-naphthylamine

C20H21N (275.1674)


   

isopropyl 4-(5-amino-1-methyl-1H-benzo[d]imidazol-2-yl)butanoate

isopropyl 4-(5-amino-1-methyl-1H-benzo[d]imidazol-2-yl)butanoate

C15H21N3O2 (275.1634)


   

2,4,6-Tri-t-butyl-nitrosobenzene

2,4,6-Tri-t-butyl-nitrosobenzene

C18H29NO (275.2249)


   

N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline

N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline

C16H26BNO2 (275.2056)


   

N-[2-(Diethylamino)ethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide

N-[2-(Diethylamino)ethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide

C16H25N3O (275.1998)


   

(1,3-dimethyl-4-phenylazepan-4-yl) propanoate

(1,3-dimethyl-4-phenylazepan-4-yl) propanoate

C17H25NO2 (275.1885)


   

tert-butyl (3S)-4-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate

tert-butyl (3S)-4-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate

C13H25NO5 (275.1733)


   

3-PENTYL-2-PHENYL-QUINOLINE

3-PENTYL-2-PHENYL-QUINOLINE

C20H21N (275.1674)


   

N-METHYL-2-(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)ACETAMIDE

N-METHYL-2-(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)ACETAMIDE

C15H22BNO3 (275.1693)


   

4-Piperidinecarboxamide,1-(phenylmethyl)-4-(propylamino)-

4-Piperidinecarboxamide,1-(phenylmethyl)-4-(propylamino)-

C16H25N3O (275.1998)


   

5-(4-methoxyphenyl)-3-methyl-1-oxa-3-azaspiro[5.5]undecane

5-(4-methoxyphenyl)-3-methyl-1-oxa-3-azaspiro[5.5]undecane

C17H25NO2 (275.1885)


   

3-(isodecyloxy)propylammonium acetate

3-(isodecyloxy)propylammonium acetate

C15H33NO3 (275.246)


   

2-CYCLOBUTOXY-6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDINE

2-CYCLOBUTOXY-6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDINE

C15H22BNO3 (275.1693)


   

2-[4-(2-methylpropyl)phenyl]-1-morpholin-4-ylpropan-1-one

2-[4-(2-methylpropyl)phenyl]-1-morpholin-4-ylpropan-1-one

C17H25NO2 (275.1885)


   

Doxylaminephenyl-d5

Doxylaminephenyl-d5

C17H17D5N2O (275.2046)


   

3-(Boc-amino)-3-(4-tetrahydrothiopyranyl)-1-propanol

3-(Boc-amino)-3-(4-tetrahydrothiopyranyl)-1-propanol

C13H25NO3S (275.1555)


   

(1S,5R)-(-)-CIS-2-OXABICYCLO[3.3.0]OCT-6-EN-3-ONE

(1S,5R)-(-)-CIS-2-OXABICYCLO[3.3.0]OCT-6-EN-3-ONE

C17H29N3 (275.2361)


   

Boc-O-tert-butyl-L-threonine

Boc-O-tert-butyl-L-threonine

C13H25NO5 (275.1733)


   

N-(2-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL)PROPAN-1-AMINE

N-(2-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL)PROPAN-1-AMINE

C16H26BNO2 (275.2056)


   

17beta-estradiol-16,16,17-d3

17beta-estradiol-16,16,17-d3

C18H21D3O2 (275.1965)


   

3-{1-[(tert-butoxy)carbonyl]piperidin-4-yl}-2-fluoropropanoic ac

3-{1-[(tert-butoxy)carbonyl]piperidin-4-yl}-2-fluoropropanoic ac

C13H22FNO4 (275.1533)


   

methyl 2-(nonylideneamino)benzoate

methyl 2-(nonylideneamino)benzoate

C17H25NO2 (275.1885)


   

1,1-dimethyl-2-(4-methoxyphenyl)ethylamine hydrochloride

1,1-dimethyl-2-(4-methoxyphenyl)ethylamine hydrochloride

C15H21N3O2 (275.1634)


   

N,N-Dimethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

N,N-Dimethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

C15H22BNO3 (275.1693)


   

2-(pyrrolidin-1-yl)pyrimidine-5-boronic acid pinacol ester

2-(pyrrolidin-1-yl)pyrimidine-5-boronic acid pinacol ester

C14H22BN3O2 (275.1805)


   

isononanal / methyl anthranilate schiffs base

isononanal / methyl anthranilate schiffs base

C17H25NO2 (275.1885)


   

Menthyl anthranilate

Menthyl anthranilate

C17H25NO2 (275.1885)


C1892 - Chemopreventive Agent > C851 - Sunscreen

   

6-Cyclopropylmethoxypyridine-3-boronic acid pinacol ester

6-Cyclopropylmethoxypyridine-3-boronic acid pinacol ester

C15H22BNO3 (275.1693)


   

4-(N,N-Dimethylaminocarbonyl)phenylboronic acid, pinacol ester

4-(N,N-Dimethylaminocarbonyl)phenylboronic acid, pinacol ester

C15H22BNO3 (275.1693)


   

1-(3,5-dimethylphenyl)-7-(1-methylethyl)-Isoquinoline

1-(3,5-dimethylphenyl)-7-(1-methylethyl)-Isoquinoline

C20H21N (275.1674)


   

N-[3-(Dimethoxymethylsilyl)propyl]-1-piperazineethanamine

N-[3-(Dimethoxymethylsilyl)propyl]-1-piperazineethanamine

C12H29N3O2Si (275.2029)


   

2-Methyl-2-propanyl N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-homoserinate

2-Methyl-2-propanyl N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-homoserinate

C13H25NO5 (275.1733)


   

N-Methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

N-Methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

C15H22BNO3 (275.1693)


   

Piperphenidol

Piperphenidol

C18H29NO (275.2249)


   

Boc-D-Thr(tBu)-OH

Boc-D-Thr(tBu)-OH

C13H25NO5 (275.1733)


   

Alphameprodine

[(3S,4R)-3-ethyl-1-methyl-4-phenylpiperidin-4-yl] propanoate

C17H25NO2 (275.1885)


C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist

   

1-[4-(dimethylamino)phenyl]-6-phenylhexatriene

1-[4-(dimethylamino)phenyl]-6-phenylhexatriene

C20H21N (275.1674)


   

2-methoxy-4-(4-pyrrolidin-1-ylpiperidin-1-yl)aniline

2-methoxy-4-(4-pyrrolidin-1-ylpiperidin-1-yl)aniline

C16H25N3O (275.1998)


   

benzyl N-(1-pyrrolidin-3-ylazetidin-3-yl)carbamate

benzyl N-(1-pyrrolidin-3-ylazetidin-3-yl)carbamate

C15H21N3O2 (275.1634)


   

benzyl 3-(3-aminoazetidin-1-yl)pyrrolidine-1-carboxylate

benzyl 3-(3-aminoazetidin-1-yl)pyrrolidine-1-carboxylate

C15H21N3O2 (275.1634)


   

5-[(1-Phenylcyclohexyl)amino]pentanoic acid

5-[(1-Phenylcyclohexyl)amino]pentanoic acid

C17H25NO2 (275.1885)


A fatty acid derivative consisting of valeric acid substituted at C-5 with an N-(1-phenylcyclohexyl)amino group.

   

3-Hydroxyhexanoylcarnitine

3-Hydroxyhexanoylcarnitine

C13H25NO5 (275.1733)


Hydroxyhexanoycarnitine is an acylcarnitine. More specifically, it is an hydroxyhexanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Hydroxyhexanoycarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine hydroxyhexanoycarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]

   

(6Z,9Z,12Z,15Z)-Octadeca-6,9,12,15-tetraenoate

(6Z,9Z,12Z,15Z)-Octadeca-6,9,12,15-tetraenoate

C18H27O2- (275.2011)


   

cis-Parinarate

cis-Parinarate

C18H27O2- (275.2011)


A straight-chain, unsaturated, long-chain fatty acid anion that is the conjugate base of cis-parinaric acid, arising from deprotonation of the carboxylic acid group.

   

All-cis-9,12-octadecadien-6-ynoic acid

All-cis-9,12-octadecadien-6-ynoic acid

C18H27O2- (275.2011)


   
   

3-Hydroxyhexanoyl-L-carnitine

3-Hydroxyhexanoyl-L-carnitine

C13H25NO5 (275.1733)


   

4-Hydroxyhexanoycarnitine

4-Hydroxyhexanoycarnitine

C13H25NO5 (275.1733)


   

(5R)-5-Hydroxyhexanoylcarnitine

(5R)-5-Hydroxyhexanoylcarnitine

C13H25NO5 (275.1733)


   

(1S,2R)-5-methoxy-1-methyl-N,N-dipropyl-1,2,3,4-tetrahydronaphthalen-2-amine

(1S,2R)-5-methoxy-1-methyl-N,N-dipropyl-1,2,3,4-tetrahydronaphthalen-2-amine

C18H29NO (275.2249)


D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists

   

N-methylcarbamic acid [(8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] ester

N-methylcarbamic acid [(8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] ester

C15H21N3O2 (275.1634)


   

1-(4-Butylbenzyl)Isoquinoline

1-(4-Butylbenzyl)Isoquinoline

C20H21N (275.1674)


   

3-(1-Piperidinyl)-1-(4-propan-2-yloxyphenyl)-1-propanone

3-(1-Piperidinyl)-1-(4-propan-2-yloxyphenyl)-1-propanone

C17H25NO2 (275.1885)


   

1-[2-(dimethylamino)ethyl]-5-methoxy-N-methyl-2-indolecarboxamide

1-[2-(dimethylamino)ethyl]-5-methoxy-N-methyl-2-indolecarboxamide

C15H21N3O2 (275.1634)


   

5-methoxy-1-methyl-N,N-dipropyl-1,2,3,4-tetrahydronaphthalen-2-amine

5-methoxy-1-methyl-N,N-dipropyl-1,2,3,4-tetrahydronaphthalen-2-amine

C18H29NO (275.2249)


   

3-ethyl-N-(2H-tetrazol-5-yl)-1-adamantanecarboxamide

3-ethyl-N-(2H-tetrazol-5-yl)-1-adamantanecarboxamide

C14H21N5O (275.1746)


   

(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C18H27O2- (275.2011)


   
   

Arginyl-threonine

Arginyl-threonine

C10H21N5O4 (275.1593)


   

(1R,2aR,8bR)-1-(hydroxymethyl)-N-propan-2-yl-2a,3,4,8b-tetrahydro-1H-azeto[2,3-c]quinoline-2-carboxamide

(1R,2aR,8bR)-1-(hydroxymethyl)-N-propan-2-yl-2a,3,4,8b-tetrahydro-1H-azeto[2,3-c]quinoline-2-carboxamide

C15H21N3O2 (275.1634)


   

(1S,2aR,8bR)-1-(hydroxymethyl)-N-propan-2-yl-2a,3,4,8b-tetrahydro-1H-azeto[2,3-c]quinoline-2-carboxamide

(1S,2aR,8bR)-1-(hydroxymethyl)-N-propan-2-yl-2a,3,4,8b-tetrahydro-1H-azeto[2,3-c]quinoline-2-carboxamide

C15H21N3O2 (275.1634)


   

2-(3-benzyl-2-oxoimidazolidin-1-yl)-N-propylacetamide

2-(3-benzyl-2-oxoimidazolidin-1-yl)-N-propylacetamide

C15H21N3O2 (275.1634)


   

4-acetamido-N-(2-aminocyclohexyl)benzamide

4-acetamido-N-(2-aminocyclohexyl)benzamide

C15H21N3O2 (275.1634)


   

N-(2-phenylethyl)decanamide

N-(2-phenylethyl)decanamide

C18H29NO (275.2249)


   

2-Aminopentadecane-1,3,4-triol

2-Aminopentadecane-1,3,4-triol

C15H33NO3 (275.246)


   

MGK-264

N-(2-Ethylhexyl)-5-norbornene-2,3-dicarboximide

C17H25NO2 (275.1885)


   

cyclobenzaprine

cyclobenzaprine

C20H21N (275.1674)


D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents M - Musculo-skeletal system > M03 - Muscle relaxants > M03B - Muscle relaxants, centrally acting agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant

   

(6Z,9Z,12Z,15Z)-Octadecatetraenoate

(6Z,9Z,12Z,15Z)-Octadecatetraenoate

C18H27O2 (275.2011)


A polyunsaturated fatty acid anion that is the conjugate base of (6Z,9Z,12Z,15Z)-octadecatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

Citronellyl anthranilate

Citronellyl anthranilate

C17H25NO2 (275.1885)


   

arginylthreonine

arginylthreonine

C10H21N5O4 (275.1593)


   

1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate

1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate

C15H21N3O2 (275.1634)


   

Hydroxyhexanoycarnitine

Hydroxyhexanoycarnitine

C13H25NO5 (275.1733)


   

trans-parinarate

trans-parinarate

C18H27O2 (275.2011)


A straight-chain, unsaturated fatty acid anion that is the conjugate base of trans-parinaric acid, arising from deprotonation of the carboxylic acid group.

   

octadecatetraenoate

octadecatetraenoate

C18H27O2. (275.2011)


A fatty acid anion containing 18 carbons and four double bonds. Formed by deprotonation of the carboxylic acid group. Major species at pH 7.3.

   

O-hydroxyhexanoyl-L-carnitine

O-hydroxyhexanoyl-L-carnitine

C13H25NO5 (275.1733)


An O-acyl-L-carnitine that is L-carnitine having a hydroxyhexanoyl group as the acyl substituent in which the position of the hydroxy group is unspecified.

   
   
   
   
   
   

1-({1,3a,8-trimethyl-2h,3h,8ah-pyrrolo[2,3-b]indol-5-yl}oxy)-n-methylmethanimidic acid

1-({1,3a,8-trimethyl-2h,3h,8ah-pyrrolo[2,3-b]indol-5-yl}oxy)-n-methylmethanimidic acid

C15H21N3O2 (275.1634)


   

n-[(2e,6e)-3,7-dimethyl-8-(4-methylfuran-2-yl)octa-2,6-dien-1-yl]guanidine

n-[(2e,6e)-3,7-dimethyl-8-(4-methylfuran-2-yl)octa-2,6-dien-1-yl]guanidine

C16H25N3O (275.1998)


   

8-hydroxy-4,11-dimethyl-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-13-one

8-hydroxy-4,11-dimethyl-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-13-one

C17H25NO2 (275.1885)


   

(2e,4e,8z,11z)-n-(2-methylpropyl)tetradeca-2,4,8,11-tetraenimidic acid

(2e,4e,8z,11z)-n-(2-methylpropyl)tetradeca-2,4,8,11-tetraenimidic acid

C18H29NO (275.2249)


   

(2s,3s,5r)-2-benzyl-5-heptylpyrrolidin-3-ol

(2s,3s,5r)-2-benzyl-5-heptylpyrrolidin-3-ol

C18H29NO (275.2249)


   

(2s,3r,6s)-6-[(1e,3e,7e,9e)-dodeca-1,3,7,9-tetraen-1-yl]-2-methylpiperidin-3-ol

(2s,3r,6s)-6-[(1e,3e,7e,9e)-dodeca-1,3,7,9-tetraen-1-yl]-2-methylpiperidin-3-ol

C18H29NO (275.2249)


   

(8s,9ar,13ar)-8-hydroxy-4,11-dimethyl-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-13-one

(8s,9ar,13ar)-8-hydroxy-4,11-dimethyl-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-13-one

C17H25NO2 (275.1885)


   

2-[6-(2-hydroxypropyl)-1-methylpiperidin-2-yl]-1-phenylethanone

2-[6-(2-hydroxypropyl)-1-methylpiperidin-2-yl]-1-phenylethanone

C17H25NO2 (275.1885)


   

6-(dodeca-1,3,5,9-tetraen-1-yl)-2-methylpiperidin-3-ol

6-(dodeca-1,3,5,9-tetraen-1-yl)-2-methylpiperidin-3-ol

C18H29NO (275.2249)


   

(8s,9as,13as)-8-hydroxy-4,11-dimethyl-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-13-one

(8s,9as,13as)-8-hydroxy-4,11-dimethyl-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-13-one

C17H25NO2 (275.1885)


   

2-[(2r,6s)-6-[(2s)-2-hydroxypropyl]-1-methylpiperidin-2-yl]-1-phenylethanone

2-[(2r,6s)-6-[(2s)-2-hydroxypropyl]-1-methylpiperidin-2-yl]-1-phenylethanone

C17H25NO2 (275.1885)


   

(2e,4e,8z,11e)-n-(2-methylpropyl)tetradeca-2,4,8,11-tetraenimidic acid

(2e,4e,8z,11e)-n-(2-methylpropyl)tetradeca-2,4,8,11-tetraenimidic acid

C18H29NO (275.2249)


   

(1s,4s,9r,10r)-9-butyl-10-propyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodec-8(12)-en-6-imine

(1s,4s,9r,10r)-9-butyl-10-propyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodec-8(12)-en-6-imine

C17H29N3 (275.2361)


   

(2e,4e,8z,10z)-n-(2-methylpropyl)tetradeca-2,4,8,10-tetraenimidic acid

(2e,4e,8z,10z)-n-(2-methylpropyl)tetradeca-2,4,8,10-tetraenimidic acid

C18H29NO (275.2249)


   

1-[6-(2-hydroxy-2-phenylethyl)-1-methylpiperidin-2-yl]propan-2-one

1-[6-(2-hydroxy-2-phenylethyl)-1-methylpiperidin-2-yl]propan-2-one

C17H25NO2 (275.1885)


   

(2s)-1-[(2s,6r)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methyl-3,6-dihydro-2h-pyridin-2-yl]propan-2-ol

(2s)-1-[(2s,6r)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methyl-3,6-dihydro-2h-pyridin-2-yl]propan-2-ol

C17H25NO2 (275.1885)


   

(1'r,2r,7's,8'r,10's)-8'-ethyl-3-methyl-2'-azaspiro[furan-2,9'-tricyclo[5.5.0.0²,¹⁰]dodecan]-5-one

(1'r,2r,7's,8'r,10's)-8'-ethyl-3-methyl-2'-azaspiro[furan-2,9'-tricyclo[5.5.0.0²,¹⁰]dodecan]-5-one

C17H25NO2 (275.1885)


   

6-methyl-13-azatetracyclo[11.3.1.0¹,⁹.0⁴,⁹]heptadecane-2,8-dione

6-methyl-13-azatetracyclo[11.3.1.0¹,⁹.0⁴,⁹]heptadecane-2,8-dione

C17H25NO2 (275.1885)


   

(2s,3r,6s)-6-[(1e,3e,5e,9e)-dodeca-1,3,5,9-tetraen-1-yl]-2-methylpiperidin-3-ol

(2s,3r,6s)-6-[(1e,3e,5e,9e)-dodeca-1,3,5,9-tetraen-1-yl]-2-methylpiperidin-3-ol

C18H29NO (275.2249)


   

4-[2-(dimethylamino)ethyl]-4-(4-methoxyphenyl)cyclohexan-1-one

4-[2-(dimethylamino)ethyl]-4-(4-methoxyphenyl)cyclohexan-1-one

C17H25NO2 (275.1885)


   

1-[6-(2-hydroxy-2-phenylethyl)-1-methyl-3,6-dihydro-2h-pyridin-2-yl]propan-2-ol

1-[6-(2-hydroxy-2-phenylethyl)-1-methyl-3,6-dihydro-2h-pyridin-2-yl]propan-2-ol

C17H25NO2 (275.1885)


   

1-[(2r,6s)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]propan-2-one

1-[(2r,6s)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]propan-2-one

C17H25NO2 (275.1885)


   

9-butyl-10-propyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodec-8(12)-en-6-imine

9-butyl-10-propyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodec-8(12)-en-6-imine

C17H29N3 (275.2361)


   

1-[(2s,6r)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]propan-2-one

1-[(2s,6r)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]propan-2-one

C17H25NO2 (275.1885)


   

(2e,4e,8z,11e)-n-[(2s)-butan-2-yl]tetradeca-2,4,8,11-tetraenimidic acid

(2e,4e,8z,11e)-n-[(2s)-butan-2-yl]tetradeca-2,4,8,11-tetraenimidic acid

C18H29NO (275.2249)


   

(8r,9as,13as)-8-hydroxy-4,11-dimethyl-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-13-one

(8r,9as,13as)-8-hydroxy-4,11-dimethyl-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-13-one

C17H25NO2 (275.1885)


   

n-(2-methylpropyl)tetradeca-2,4,8,11-tetraenimidic acid

n-(2-methylpropyl)tetradeca-2,4,8,11-tetraenimidic acid

C18H29NO (275.2249)


   

(2e,4e,8z,11z)-n-[(2s)-butan-2-yl]tetradeca-2,4,8,11-tetraenimidic acid

(2e,4e,8z,11z)-n-[(2s)-butan-2-yl]tetradeca-2,4,8,11-tetraenimidic acid

C18H29NO (275.2249)


   

1-{[(3as,8ar)-1,3a,8-trimethyl-2h,3h,8ah-pyrrolo[2,3-b]indol-5-yl]oxy}-n-methylmethanimidic acid

1-{[(3as,8ar)-1,3a,8-trimethyl-2h,3h,8ah-pyrrolo[2,3-b]indol-5-yl]oxy}-n-methylmethanimidic acid

C15H21N3O2 (275.1634)


   

n-[3,7-dimethyl-8-(4-methylfuran-2-yl)octa-2,6-dien-1-yl]guanidine

n-[3,7-dimethyl-8-(4-methylfuran-2-yl)octa-2,6-dien-1-yl]guanidine

C16H25N3O (275.1998)


   

(2s)-1-[(2r,6s)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methyl-3,6-dihydro-2h-pyridin-2-yl]propan-2-ol

(2s)-1-[(2r,6s)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methyl-3,6-dihydro-2h-pyridin-2-yl]propan-2-ol

C17H25NO2 (275.1885)


   

(2r)-1-[(2r,6s)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methyl-5,6-dihydro-2h-pyridin-2-yl]propan-2-ol

(2r)-1-[(2r,6s)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methyl-5,6-dihydro-2h-pyridin-2-yl]propan-2-ol

C17H25NO2 (275.1885)


   

(2s)-2-{[(3r)-1,3-dihydroxydecylidene]amino}-3-hydroxypropanoic acid

(2s)-2-{[(3r)-1,3-dihydroxydecylidene]amino}-3-hydroxypropanoic acid

C13H25NO5 (275.1733)


   

(2e,4e,8z,10e,12e)-n-(2-hydroxypropan-2-yl)tetradeca-2,4,8,10,12-pentaenimidic acid

(2e,4e,8z,10e,12e)-n-(2-hydroxypropan-2-yl)tetradeca-2,4,8,10,12-pentaenimidic acid

C17H25NO2 (275.1885)


   

6-(dodeca-1,3,7,9-tetraen-1-yl)-2-methylpiperidin-3-ol

6-(dodeca-1,3,7,9-tetraen-1-yl)-2-methylpiperidin-3-ol

C18H29NO (275.2249)


   

(2s,3s,5e,9z,12z,15z)-2-aminooctadeca-5,9,12,15,17-pentaen-3-ol

(2s,3s,5e,9z,12z,15z)-2-aminooctadeca-5,9,12,15,17-pentaen-3-ol

C18H29NO (275.2249)


   

(1s,4r,6r,9r)-6-methyl-13-azatetracyclo[11.3.1.0¹,⁹.0⁴,⁹]heptadecane-2,8-dione

(1s,4r,6r,9r)-6-methyl-13-azatetracyclo[11.3.1.0¹,⁹.0⁴,⁹]heptadecane-2,8-dione

C17H25NO2 (275.1885)


   

(2r,3s,5e,9z,12z,15z)-2-aminooctadeca-5,9,12,15,17-pentaen-3-ol

(2r,3s,5e,9z,12z,15z)-2-aminooctadeca-5,9,12,15,17-pentaen-3-ol

C18H29NO (275.2249)


   

1-[6-(2-hydroxy-2-phenylethyl)-1-methyl-5,6-dihydro-2h-pyridin-2-yl]propan-2-ol

1-[6-(2-hydroxy-2-phenylethyl)-1-methyl-5,6-dihydro-2h-pyridin-2-yl]propan-2-ol

C17H25NO2 (275.1885)


   

2-aminooctadeca-5,9,12,15,17-pentaen-3-ol

2-aminooctadeca-5,9,12,15,17-pentaen-3-ol

C18H29NO (275.2249)